Roden, Michael
Shulman, Gerald I.
Article History
Received: 27 March 2019
Accepted: 18 September 2019
First Online: 4 December 2019
Competing interests
: M.R. is on the scientific advisory boards of Bristol-Myers Squibb, Eli Lilly, Gilead Sciences, NovoNordisk, Servier Laboratories, Target Pharmasolutions and Terra Firma and receives investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone and Sanofi–Aventis. G.I.S. is on the scientific advisory boards of Merck, NovoNordisk, Gilead Sciences, AstraZeneca, Aegerion, iMBP, Janssen Research and Development and receives investigator-initiated support from Gilead Sciences, Merck and AstraZeneca.